Inion Oy
29 April 2008





                                    Inion Oy

                           ("Inion or the "Company")



                       Update on US Commercial Operations



Tampere, Finland and Guildford, UK. 29 April 2008, Inion (LSE: IIN.L), a company
focused on the development and commercialisation of novel biodegradable medical
implants, today provides an update on its US commercial operations.



Dave Hawkes has been promoted to US National Sales Director from his previous
role as Regional Sales Manager for the Central USA region. He takes over the
responsibilities held by Scott Pravda, who has left his position as President,
Inion USA and taken up a new role as an exclusive independent distributor for
Inion products for the South Florida area.



Dave joined Inion in mid-2007 and has significant sales and marketing experience
in the medical implants industry from Stryker and latterly DePuy. In this new
role, and working closely with Chris Lee (CEO) and David Follows (CCO), he will
take on responsibility for the development and growth of Inion's trauma and
spinal surgery businesses in the USA, including overseeing the appointment and
training of new independent distributors.



Chris Lee, CEO of Inion, said: "Dave has been highly effective in his role as
Regional Sales Manager and has built a comprehensive distribution network in the
Central USA region, which is already delivering impressive sales growth. In
achieving this in such a short time, Dave has also demonstrated he has the
qualities necessary to run the US commercial operation and his promotion to this
crucially important role for Inion is well deserved."



He added, "We are extremely appreciative of Scott's efforts over the past year
and are very pleased he has decided to act as an independent distributor for
Inion products in the South Florida area, demonstrating his belief in the
clinical appeal of our growing product range. He has many significant clinical
relationships and knowledge of this market, which will drive his success in this
territory."



Dave Hawkes, said, "I am very excited to have been given this important
opportunity. Inion has created a portfolio of excellent products targeting the
orthopaedic trauma and spinal surgery market segment and I am confident that its
commercial strategy will be a great success. Scott has left the US operation in
great shape and it is now well positioned to further accelerate sales across the
country. I am really looking forward to building on this foundation to progress
Inion's business in this important market."

                                     -ends-



For further information, please contact:


Inion Oy                                            Tel: +44 (0)1483 685390
Chris Lee, Chief Executive Officer
Julien Cotta, Chief Financial Officer


Citigate Dewe Rogerson                              Tel: +44 (0)207 638 9571
Mark Swallow / David Dible




About Inion (www.inion.com)

Inion Oy is a medical devices company focused on the development and successful
commercialisation of innovative and unique biodegradable and bioactive surgical
implants in selected high value orthopaedic market segments.



Inion's core expertise and technology lies in the design and manufacture of
innovative biodegradable plates, screws, pins and membranes, which are used to
enhance the healing of bone or soft tissue injuries to the skeleton, such as
those caused by trauma or by reconstructive surgery. Inion implants are made
from its proprietary Inion Optima(TM) family of biomaterials, with properties
tailored for specific surgical applications, in terms of strength, flexibility
and rate of degradation


Inion is also focused on developing proprietary new bioactive and biodegradable
biomaterials that promote bone healing and accelerate patient rehabilitation.



Inion was incorporated in early 2000 and listed on the Official List of the UK
Listing Authority in December 2004 (ticker: IIN). The Company has offices in the
UK and USA, and its head office, R&D and production facilities are in Tampere,
Finland.



This announcement includes "forward-looking statements" which include all
statements other than statements of historical facts, including, without
limitation, those regarding the Group's financial position, business strategy,
plans and objectives of management for future operations (including development
plans and objectives relating to the Group's products), and any statements
preceded by, followed by or that include forward-looking terminology such as the
words "targets", "believes", "estimates", "expects", "aims", "intends", "will",
"can", "may", "anticipates", "would", "should", "could" or similar expressions
or the negative thereof. Such forward-looking statements involve known and
unknown risks, uncertainties and other important factors beyond the Group's
control that could cause the actual results, performance or achievements of the
Group to be materially different from future results, performance or
achievements expressed or implied by such forward-looking statements. Such
forward-looking statements are based on numerous assumptions regarding the
Group's present and future business strategies and the environment in which the
Group will operate in the future. Among the important factors that could cause
the Group's actual results, performance or achievements to differ materially
from those in forward-looking statements include those relating to Inion's
funding requirements, regulatory approvals, reliance on third parties,
intellectual property, key personnel and other factors. These forward-looking
statements speak only as at the date of this announcement. The Group expressly
disclaims any obligation or undertaking to disseminate any updates or revisions
to any forward-looking statements contained in this announcement to reflect any
change in the Group's expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are based. As a result
of these factors, prospective investors are cautioned not to rely on any
forward-looking statement.






                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

NRAUKVRRWNRSUAR
Inion Oy (LSE:IIN)
Historical Stock Chart
From Sep 2024 to Oct 2024 Click Here for more Inion Oy Charts.
Inion Oy (LSE:IIN)
Historical Stock Chart
From Oct 2023 to Oct 2024 Click Here for more Inion Oy Charts.